Evidence for impaired amyloid β clearance in Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 5, Issue 4, 2013, Pages

  Wildsmith, Kristin R ^a   Holley, Monica ^b   Savage, Julie C ^b   Skerrett, Rebecca ^b   Landreth, Gary E ^b  

^a GENENTECH INC   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN; CATABOLISM; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHOLESTEROL METABOLISM; GENOTYPE; HOMEOSTASIS; IMMUNOREACTIVITY; MICRODIALYSIS; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

EID: 84880256692     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt187     Document Type: Review

References (60)

1. Global prevalence of dementia: a Delphi consensus study. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M, Alzheimer's Disease International, Lancet 2005 366 2112 2117 16360788 (Pubitemid 41797645)
2. Clearing the brain's amyloid cobwebs. Selkoe DJ, Neuron 2001 32 177 180 10.1016/S0896-6273(01)00475-5 11683988 (Pubitemid 33030186)
3. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM, J Neurosci 2003 23 8844 8853 14523085 (Pubitemid 37210896)
4. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Abeta clearance in a mouse model of beta-amyloidosis. Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM, Proc Natl Acad Sci USA 2012 109 15502 15507 10.1073/pnas.1206446109 22927427
5. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. Miners JS, Barua N, Kehoe PG, Gill S, Love S, J Neuropathol Exp Neurol 2011 70 944 959 10.1097/NEN.0b013e3182345e46 22002425
6. Dynamic analysis of amyloid beta-protein in behaving mice reveals opposing changes in ISF versus parenchymal Abeta during age-related plaque formation. Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ, J Neurosci 2011 31 15861 15869 10.1523/JNEUROSCI.3272-11.2011 22049429
7. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM, J Neurosci 2009 29 10706 10714 10.1523/JNEUROSCI.2637-09.2009 19710322
8. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM, Sci Transl Med 2011 3 89ra57 10.1126/scitranslmed. 3002156 21715678
9. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM, Nat Med 2006 12 856 861 10.1038/nm1438 16799555 (Pubitemid 44050079)
10. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ, Science 2010 330 1774 10.1126/science.1197623 21148344
11. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM, JAMA 1997 278 1349 1356 10.1001/jama.1997.03550160069041 9343467 (Pubitemid 27449696)
12. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, et al. Nat Genet 1994 7 180 184 10.1038/ng0694-180 7920638 (Pubitemid 24174658)
13. APOE genotype effects on Alzheimer's disease onset and epidemiology. Ashford JW, J Mol Neurosci 2004 23 157 165 10.1385/JMN:23:3:157 15181244 (Pubitemid 41389382)
14. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA, Science 1993 261 921 923 10.1126/science.8346443 8346443 (Pubitemid 23275809)
15. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner C, Cache County Study Investigators, Arch Gen Psychiatry 2004 61 518 524 10.1001/archpsyc.61.5.518 15123497 (Pubitemid 38620851)
16. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, Hansen JC, Sullivan PM, Paul SM, J Neurosci 2009 29 6771 6779 10.1523/JNEUROSCI.0887- 09.2009 19474305
17. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM, Proc Natl Acad Sci USA 2000 97 2892 2897 10.1073/pnas.050004797 10694577 (Pubitemid 30159268)
18. Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Mann DM, Iwatsubo T, Pickering-Brown SM, Owen F, Saido TC, Perry RH, Neurosci Lett 1997 221 81 84 10.1016/S0304-3940(96)13294-8 9121705 (Pubitemid 27049203)
19. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Bu G, Nat Rev Neurosci 2009 10 333 344 10.1038/nrn2620 19339974
20. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL, J Biol Chem 2004 279 41197 41207 10.1074/jbc.M407962200 15269218 (Pubitemid 39287722)
21. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver × receptors. Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P, Proc Natl Acad Sci USA 2007 104 10601 10606 10.1073/pnas.0701096104 17563384 (Pubitemid 47185711)
22. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, Frangione B, Ghiso J, Biochem J 2000 348 Pt 2 359 365 10816430 (Pubitemid 30345209)
23. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM, J Biol Chem 2005 280 43236 43242 10.1074/jbc.M508780200 16207708 (Pubitemid 43049290)
24. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. Koldamova R, Staufenbiel M, Lefterov I, J Biol Chem 2005 280 43224 43235 10.1074/jbc.M504513200 16207713 (Pubitemid 43049289)
25. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, Poirier J, Van Nostrand W, Wellington CL, J Biol Chem 2005 280 43243 43256 10.1074/jbc.M508781200 16207707 (Pubitemid 43049291)
26. ApoE promotes the proteolytic degradation of Abeta. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE, Neuron 2008 58 681 693 10.1016/j.neuron.2008.04.010 18549781 (Pubitemid 351778466)
27. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. Michikawa M, Fan QW, Isobe I, Yanagisawa K, J Neurochem 2000 74 1008 1016 10.1046/j.1471-4159.2000.0741008.x 10693931 (Pubitemid 30104296)
28. Isoform-dependent cholesterol efflux from macrophages by apolipoprotein E is modulated by cell surface proteoglycans. Hara M, Matsushima T, Satoh H, Iso-o N, Noto H, Togo M, Kimura S, Hashimoto Y, Tsukamoto K, Arterioscler Thromb Vasc Biol 2003 23 269 274 10.1161/01.ATV.0000054199.78458.4B 12588770 (Pubitemid 36231939)
29. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. Fitz NF, Cronican AA, Saleem M, Fauq AH, Chapman R, Lefterov I, Koldamova R, J Neurosci 2012 32 13125 13136 10.1523/JNEUROSCI.1937-12.2012 22993429
30. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. St rittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD, Proc Natl Acad Sci USA 1993 90 8098 8102 10.1073/pnas.90.17.8098 8367470 (Pubitemid 23260862)
31. Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. Holtzman DM, J Mol Neurosci 2001 17 147 155 10.1385/JMN:17:2:147 11816788 (Pubitemid 33063519)
32. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM, Proc Natl Acad Sci USA 1999 96 15233 15238 10.1073/pnas.96.26.15233 10611368 (Pubitemid 30019795)
33. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV, J Clin Invest 2000 106 1489 1499 10.1172/JCI10498 11120756 (Pubitemid 32038587)
34. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K, Brain Res 1991 541 163 166 10.1016/0006-8993(91)91092-F 2029618
35. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN, J Neurochem 1997 68 721 725 9003062 (Pubitemid 27044736)
36. Isoform-specific binding of apolipoprotein E to beta-amyloid. La Du MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE, J Biol Chem 1994 269 23403 23406 8089103
37. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Aleshkov S, Abraham CR, Zannis VI, Biochemistry 1997 36 10571 10580 10.1021/bi9626362 9265639 (Pubitemid 27374151)
38. Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. DeMattos RB, J Mol Neurosci 2004 23 255 262 10.1385/JMN:23:3:255 15181254
39. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV, J Clin Invest 2008 118 4002 4013 10.1172/JCI36663 19033669
40. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM, Proc Natl Acad Sci USA 2013 110 1807 1816 10.1073/pnas.1220484110 23620513
41. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P, Mol Cell 2001 7 161 171 10.1016/S1097-2765(01)00164-2 11172721 (Pubitemid 32162909)
42. Activation of liver × receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Morales JR, Ballesteros I, Deniz JM, Hurtado O, Vivancos J, Nombela F, Lizasoain I, Castrillo A, Moro MA, Circulation 2008 118 1450 1459 10.1161/CIRCULATIONAHA.108.782300 18794391
43. A liver × receptor and retinoid × receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM, J Neurochem 2004 88 623 634 10.1111/j.1471-4159.2004.02183.x 14720212 (Pubitemid 38140207)
44. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver × receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, Chan J, Fan J, Collins J, Wellington CL, J Biol Chem 2010 285 34144 34154 10.1074/jbc.M110.108100 20739291
45. Direct and potent regulation of gamma-secretase by its lipid microenvironment. Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ, J Biol Chem 2008 283 22529 22540 10.1074/jbc.M801925200 18539594
46. Critical role of astroglial apolipoprotein E and liver × receptor-alpha expression for microglial Abeta phagocytosis. Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JÅ Holtzman DM, Heneka MT, J Neurosci 2011 31 7049 7059 10.1523/JNEUROSCI.6546-10.2011 21562267
47. HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide. Giunta B, Zhou Y, Hou H, Rrapo E, Fernandez F, Tan J, Int J Clin Exp Pathol 2008 1 260 275 18784813
48. Apolipoprotein E promotes beta-amyloid trafficking and degradation by modulating microglial cholesterol levels. Lee CY, Tse W, Smith JD, Landreth GE, J Biol Chem 2012 287 2032 2044 10.1074/jbc.M111.295451 22130662
49. The liver × receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS, J Biol Chem 2005 280 4079 4088 15557325 (Pubitemid 40288571)
50. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS, Mol Cell Neurosci 2007 34 621 628 10.1016/j.mcn.2007.01.011 17336088 (Pubitemid 46483091)
51. Liver × receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. Fitz NF, Cronican A, Pham T, Fogg A, Fauq AH, Chapman R, Lefterov I, Koldamova R, J Neurosci 2010 30 6862 6872 10.1523/JNEUROSCI.1051-10.2010 20484628
52. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE, Science 2012 335 1503 1506 10.1126/science.1217697 22323736
53. Lipid metabolism and neuroinflammation in Alzheimer's disease: a role for liver × receptors. Kang J, Rivest S, Endocr Rev 2012 33 715 746 10.1210/er.2011-1049 22766509
54. PPARs in the brain. Heneka MT, Landreth GE, Biochim Biophys Acta 2007 1771 1031 1045 10.1016/j.bbalip.2007.04.016 17569578 (Pubitemid 47208548)
55. PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT, J Neurosci 2012 32 17321 17331 10.1523/JNEUROSCI.1569-12.2012 23197723
56. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Zlokovic BV, Nat Rev Neurosci 2011 12 723 738 22048062
57. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. Deane R, Bell RD, Sagare A, Zlokovic BV, CNS Neurol Disord Drug Targets 2009 8 16 30 10.2174/ 187152709787601867 19275634
58. Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. Van Uden E, Mallory M, Veinbergs I, Alford M, Rockenstein E, Masliah E, J Neurosci 2002 22 9298 9304 12417655 (Pubitemid 35356173)
59. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B, Nat Med 2003 9 907 913 10.1038/nm890 12808450 (Pubitemid 36889934)
60. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV, J Cereb Blood Flow Metab 2007 27 909 918 17077814 (Pubitemid 46659038)